
Opinion|Videos|November 20, 2025
Using TDMs to Improve Care and Communication
Author(s)Jonathan M. Meyer, MD, DLFAPA
Reviewing TDM’s evidence-based rationale, its clinical utility, and connection to outcomes.
Advertisement
This video covers the following questions:
- Can you walk us through the typical therapeutic range—and what factors can influence individual variability?
- How can TDM help clinicians differentiate between treatment resistance due to pharmacokinetic factors (like metabolism) versus true nonresponse? and What role does TDM play in preventing toxicity, including dose-related adverse effects such as seizures or sedation?
- How might TDM support patient adherence and shared decision-making in clinical practice?
Advertisement
Related to this article

Bessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.

Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.

In this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic
2
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
3
The New Ketamine Metabolite: A Conversation With Carlos Zarate, MD; Todd Gould, MD; and Craig J. Thomas, PhD
4
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
5




